Pfizer Ventures

Bio Protocol is a decentralized science (DeSci) platform where people can fund, develop and govern tokenized early-stage scientific research from universities, companies and researchers.

AI & Machine LearningBiotechCrypto & Web3

Co-investorsBinance LabsBig Brain HoldingsPolymorphic CapitalSerafundSignature VenturesSMAPE Capital+3 more

Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.

AI & Machine LearningBiotechDeep TechHealthtech

Jim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)Jacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in

Co-investorsNexTech VenturesThird Rock VenturesNextech InvestPfizer Venture InvestmentsShangBay Capital LLCAgent Capital

Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.

BiotechHealthtechLeuven, BE

Federico Grossi(Clinical Advisor & Acting CMO)

Co-investorsDroia VenturesVIBPfizer Venture Investments

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.

BiotechHealthtech

Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)

Co-investorsSanofi VenturesTaiho Ventures, LLCSamsara BioCapitalCanaan PartnersConnecticut InnovationsPfizer Venture Investments+3 more

TRIMTech Therapeutics is a biotechnology company focused on drug discovery and development, backed by investors including Cambridge Innovation Capital and BGF.

BiotechDeep TechLongevityMedical DevicesCambridge, GB

Damian Crowther, PhD FRCP(Co-founder, Head of Research)Dr. Leo James(Co-founder, Group Leader at MRC Laboratory of Molecular Biology)Dr. William McEwan(Co-founder, Group Leader at UK Dementia Research Institute, University of Cambridge)Nicki Thompson, PhD(CEO)Nicki Thompson(CEO)

Co-investorsCambridge Innovation CapitalSV Health InvestorsPfizer Venture Investments

BlueLight Therapeutics develops novel drug molecules using a proprietary structure-based discovery platform targeting high-value therapeutic targets in life sciences.

AI & Machine LearningBiotechDeep TechSouth San Francisco, US

Ariel G. Notcovich(Founder & CEO)Mark Gallop(CSO)Mira Chaurushiya(CBO)Anjanabha Saha(VP, Discovery)

Co-investors5AM VenturesPfizer Venture Investments

Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.

BiotechDeep TechMedical Devices

George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)

Co-investorsRA CapitalSamsara BioCapitalSV Health InvestorsPfizer Venture InvestmentsM Ventures

Enodia Therapeutics develops small-molecule therapies that target protein degradation at the point of synthesis using a machine learning-enabled platform.

AI & Machine LearningBiotechDeep Tech

Yves Ribeill(CEO)

Co-investorsBpifranceElaiaPfizer Venture Investments

EvolveImmune develops immunotherapy treatments for cancer patients.

BiotechHealthtechMedical Devices

Stephen Bloch(Co-founder and Chief Executive Officer)Jay Fine(President, Research and Development)

Co-investorsSolasta VenturesPfizer Venture Investments

Levicept is a company in the life sciences sector with backing from prominent healthcare and pharmaceutical investors including Medicxi, Pfizer Ventures, Gilde Healthcare, and Advent Life Sciences.

BiotechHealthtechMedical Devices

Simon Westbrook(Founder and CSO)

Co-investorsAdvent Life SciencesGilde HealthcareIndex VenturesMedicxiPfizer Venture Investments

Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome.

BiotechHealthtechLeuven, BE

Federico Grossi(Clinical Advisor & Acting CMO)

Co-investorsDroia VenturesVIBPfizer Venture Investments

Palleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms.

BiotechDigital HealthMedical Devices

Jim Broderick(Co-Founder)Li Peng(Chief Scientific Officer)Stefani Wolff(Chief Development Officer)

Co-investorsMatrix Capital ManagementPfizer Venture Investments

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

Patrick Trojer(President & CEO, Co-founder)

Co-investorsAtlas VentureAscenta CapitalBessemer Venture PartnersLightspeed Venture PartnersRA CapitalPfizer Venture Investments

Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.

ConsumerGamingBaku, AZ

Co-investorsAtlas VentureMission BiocapitalPfizer Venture InvestmentsPivotal Life Sciences

Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.

AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US

Max Mumbach(Founding Scientist, Target Discovery)inJeffrey Verboon(Founding Scientist, Computational Biology)inAnsu Satpathy(Founder)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)Howard Chang(Co-founder)in

Co-investors8VCAndreessen HorowitzArtis VenturesGlobal BioAccess FundHAWKTAILPfizer Venture Investments+6 more

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in

BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in

Co-investorsMPM BioImpactPfizer Venture InvestmentsBiotechnology Value FundMirae Asset Venture InvestmentPolaris PartnersTaiho Ventures, LLC

DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.

BiotechHealthtechCambridge, US

Nenad Grmusa(Chief Executive Officer)inJohn McCabe(Chief Financial and Operating Officer)

Co-investorsAlta PartnersAstellas Venture Management LLCDC Investment PartnersLongwood FundPfizer Venture InvestmentsUTokyo Innovation Platform Co. Ltd.+1 more

Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.

AI & Machine LearningFuture of WorkHR TechTokyo, JP

Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))

Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalCasdin CapitalInvus+2 more

Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.

BiotechDigital HealthHealthtechMedical DevicesOxford, GB

Peter Joyce(Co-founder)inTom McCarthy(Co-founder)in

Co-investorsAndera PartnersCanaan PartnersOxford Science EnterprisesPfizer Venture InvestmentsBritish Patient CapitalEarlybird Venture Capital

Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.

BiotechHealthtechMedical Devices

Co-investorsBioMedPartnersLightspeed Venture PartnersMission BiocapitalPfizer Venture Investmentsredalpine

Mediartx develops novel therapies for patients with fibrotic diseases.

BiotechMedical DevicesBoston, US

Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)

Co-investorsLongwood FundMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture InvestmentsShangBay Capital LLC+2 more

BiotechKingston, US

Robert B. Nelson(Executive Officer, Director)Frank S. Menniti(Executive Officer, Director)inStevin Zorn(Executive Officer, Director)inIsaac Stoner(CEO)in

BoardRichard G. Horan(Director)Reetika Bhardwaj(Director)

Co-investorsPfizer Venture InvestmentsDolby Family VenturesSlater Technology Fund

Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.

BiotechMedical Devices

Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in

Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsSofinnova Partners+3 more

Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.

AI & Machine LearningBiotechDeep Tech

Co-investorsM VenturesOxford Science EnterprisesPfizer Venture InvestmentsBritish Patient CapitalJJDC

BiotechWaltham, US

James W. Broderick(Executive Officer, Director)John Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)

BoardJens Eckstein(Director)

Co-investorsSR One Capital ManagementTakeda VenturesVertex Ventures HC

STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.

BiotechHealthtechMedical Devices

Co-investorsCambridge Innovation CapitalFast Track InitiativeM VenturesPfizer Venture InvestmentsSeroba Life SciencesTaiho Ventures, LLC+1 more

Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies.

AI & Machine LearningBiotechDigital HealthMedical DevicesAnn Arbor, US

Daniel Rhodes(Executive Officer, Director)Matthew Martin(Executive Officer)Jeffrey Williams(Executive Officer, Director)

BoardChristopher O'Donnell(Director)inDavid Rubin(Director)inJames Pavlik(Director)in

Co-investorsArboretum VenturesPfizer Venture InvestmentsDeerfield Management CompanyMerck Global Health Innovation Fund